3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Glioblastoma
22
Glioma
11
Neoplasms
6
Brain Neoplasms
6
Astrocytoma
6
Gliosarcoma
5
Neuroblastoma
4
Sarcoma, Ewing
3
Sarcoma
2
Rhabdomyosarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Medulloblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Wilms Tumor
1
Spinal Cord Neoplasms
1
Rhabdoid Tumor
1
Refractory Solid Tumors
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm Metastasis
1
Melanoma, Cutaneous Malignant
1
Melanoma
1
Lymphoma, Follicular
1
Hepatoblastoma
1
Ganglioneuroblastoma
1
Interventions
Bevacizumab
12
olaparib
10
Paclitaxel
10
Carboplatin
10
liposomal doxorubicin
7
Specimen Handling
7
Magnetic Resonance Spectroscopy
6
mirvetuximab soravtansine
4
Topotecan
4
Taxes
4
Immunoglobulin G
4
Gemcitabine
4
Disulfides
4
Biopsy
4
pembrolizumab
3
cediranib
3
Oxaliplatin
2
Doxorubicin
2
1-dodecylpyridoxal
2
tremelimumab
1
trastuzumab deruxtecan
1
sotorasib
1
sarilumab
1
palbociclib
1
niraparib
1
nilotinib
1
neratinib
1
irinotecan sucrosofate
1
ipatasertib
1
dehydroftorafur
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Temozolomide
×
30 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled